Dr. Roxana Schillaci is a Principal Researcher (Investigadora Principal) at the Laboratorio de Mecanismos Moleculares de Carcinogénesis, part of the Instituto de Biología y Medicina Experimental (IBYME), which is affiliated with the Argentine National Scientific and Technical Research Council (CONICET) in Buenos Aires, Argentina. She is a senior immunologist with long-standing expertise in tumor immunology, cytokine and growth factor signaling, and breast cancer research.
Her work focuses on the molecular mechanisms underlying therapy resistance in breast cancer, particularly examining how cross-talk between signaling pathways such as tumor necrosis factor alpha (TNFα) and HER2 influences tumor progression and treatment outcomes. Schillaci’s research has contributed to identifying novel mechanisms — including the role of mucin 4 (MUC4) as a resistance biomarker — that may help overcome resistance to therapies like trastuzumab.
Schillaci has authored and co-authored numerous scientific publications in internationally indexed journals and maintains an active researcher profile on platforms such as ResearchGate, where her work on experimental biology and immunology is catalogued.
Dra. Roxana Schillaci
Laboratorio de Inmunología Tumoral
Instituto de Biología y Medicina Experimental
Vuelta de Obligado 2490
(1428) Buenos Aires, Argentina
https://ibyme.org.ar/investigacion/laboratorios/inmunologia-tumoral/